Jazz Pharmaceuticals (JAZZ) Revenue (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Revenue of $1.1 billion for Q1 2026, up 19.06% year-over-year from $897.8 million in Q1 2025, and down 10.77% quarter-over-quarter from $1.2 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Revenue (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Revenue history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.
- In Q1 2026, Revenue rose 19.06% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.4 billion (up 9.2% YoY), while the FY2025 annual figure was $4.3 billion, up 4.88% from the prior year.
- Revenue for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
- The five-year high for Revenue was $1.2 billion in Q4 2025, with the low at $813.7 million in Q1 2022.
- The 5-year median for Revenue is $972.1 million (2023), against an average of $994.1 million.
- The sharpest annual moves came in 2022 and 2025: Revenue jumped 33.93% in 2022, then declined 0.46% in 2025.
- Jazz Pharmaceuticals' Revenue stood at $972.1 million in 2022, then advanced by 4.1% to $1.0 billion in 2023, then climbed by 7.53% to $1.1 billion in 2024, then gained by 10.09% to $1.2 billion in 2025, then declined by 10.77% to $1.1 billion in 2026.
- Business Quant data shows JAZZ's Revenue at $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 1.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Bn |
| Mar 31, 2026 | 1.07 Bn |
| Dec 31, 2025 | 1.20 Bn |
| Sep 30, 2025 | 1.13 Bn |
| Jun 30, 2025 | 1.05 Bn |
| Mar 31, 2025 | 897.80 Mn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | 1.02 Bn |
| Mar 31, 2024 | 901.98 Mn |
| Dec 31, 2023 | 1.01 Bn |
| Sep 30, 2023 | 972.14 Mn |
| Jun 30, 2023 | 957.32 Mn |
| Mar 31, 2023 | 892.81 Mn |
| Dec 31, 2022 | 972.12 Mn |
| Sep 30, 2022 | 940.65 Mn |
| Jun 30, 2022 | 932.88 Mn |
| Mar 31, 2022 | 813.72 Mn |
| Dec 31, 2021 | 896.73 Mn |
| Sep 30, 2021 | 838.12 Mn |